Stryker Co. (NYSE:SYK) Shares Bought by New York Life Investment Management LLC

New York Life Investment Management LLC lifted its holdings in Stryker Co. (NYSE:SYK) by 0.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,144 shares of the medical technology company’s stock after purchasing an additional 390 shares during the period. New York Life Investment Management LLC’s holdings in Stryker were worth $16,614,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in SYK. Dunhill Financial LLC grew its position in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Stryker during the 4th quarter worth $30,000. BankPlus Trust Department acquired a new stake in shares of Stryker during the fourth quarter worth $33,000. Darwin Wealth Management LLC purchased a new stake in shares of Stryker during the third quarter valued at $36,000. Finally, Activest Wealth Management purchased a new stake in shares of Stryker during the fourth quarter valued at $36,000. 77.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SYK has been the topic of several recent analyst reports. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a report on Tuesday. JMP Securities restated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. BTIG Research raised their price objective on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Truist Financial boosted their target price on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Finally, Evercore ISI increased their target price on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average target price of $422.15.

Stryker Trading Up 0.3 %

Shares of NYSE SYK opened at $391.54 on Thursday. The business has a 50 day simple moving average of $379.42 and a 200 day simple moving average of $370.37. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a market cap of $149.40 billion, a price-to-earnings ratio of 50.46, a PEG ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the business earned $3.46 earnings per share. On average, research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.